Welcome to our dedicated page for Vireo Growth news (Ticker: VREOF), a resource for investors and traders seeking the latest updates and insights on Vireo Growth stock.
Vireo Growth Inc. (VREOF) generates a steady flow of news driven by its activities in the cannabis industry, including medical and adult-use operations, multi-state expansion, and corporate transactions. As a company that describes itself as a pioneering medical cannabis operator founded in 2014, Vireo uses press releases to communicate developments in its retail footprint, cultivation and production capacity, and strategic initiatives.
Recent news items highlight several key themes. One is geographic expansion and market entry. Vireo announced an Agreement and Plan of Merger to acquire Eaze Inc., a vertically integrated cannabis retailer and delivery technology platform with operations in California, Florida, and Colorado. The company states that this transaction is intended to mark its entry into California and Florida and to strengthen its position in Colorado, with Eaze becoming a wholly owned subsidiary upon closing.
Another recurring theme is M&A and capital structure activity. Vireo has reported entering into agreements to acquire a majority of Schwazze’s senior secured convertible notes, participating in a restructuring support agreement that contemplates an asset sale to a new entity to be majority-owned by Vireo, and negotiating an Asset Purchase Agreement to acquire Colorado dispensary assets from PharmaCann Inc. These announcements detail transaction terms, consideration in subordinate voting shares, and conditions such as regulatory approvals.
Operational updates also feature prominently. Vireo issued a release announcing the launch of adult-use cannabis sales in Minnesota at its Green Goods dispensaries, noting that it dispenses both medical and adult-use products at eight locations in the state. Quarterly earnings releases provide summaries of financial performance, state-by-state revenue, and non-GAAP metrics, accompanied by management commentary on integration of acquisitions and portfolio development.
Investors and observers who follow VREOF news can use this stream of announcements to monitor transaction progress, regulatory milestones, market entries, adult-use launches, litigation resolutions, and financial reporting updates, all of which are documented through Globe Newswire releases and linked SEC filings.
Vireo Growth (OTCQX: VREOF) updated a nonbinding MOU to acquire Hawthorne from ScottsMiracle-Gro, targeting completion after five business days and planning a share-based transaction in Q2 2026.
The contemplated deal includes US$35M cash, ~US$50M net working capital, ~US$20M inventory, issuance of 206M shares and warrants for 80M shares exercisable at US$0.85 for five years; appointment of Chris Hagedorn to Vireo’s board is planned upon closing and shareholder approval.
Vireo Growth (CSE: VREO; OTCQX: VREOF) closed its acquisition of certain Schwazze assets on March 24, 2026, acquiring 45 dispensaries (24 in Colorado, 21 in New Mexico) and one manufacturing facility in each state at an assumed share price of $0.661.
The transaction implies an estimated valuation of under 4x pro forma EBITDA. Justin Dye will become chairman of the Colorado and New Mexico business and Forrest Hoffmaster will be CEO of that regional business. Management cites a potential long‑term retail footprint of over 75 dispensaries, subject to approvals and capital.
Vireo Growth (OTCQX: VREOF) reported Q4 FY2025 GAAP revenue of $104.5M, up 317.7% YoY, driven by recent M&A activity. Pro forma Q4 revenue was $104.5M (26.1% above pro forma prior-year). Q4 cash was $122.5M, and multiple Colorado retail acquisitions plus an MOU for Hawthorne are expected to close in H1 2026.
Q4 adjusted EBITDA was $29.5M (28.2% margin); same-store sales ex-Minnesota rose 11.3% YoY, and wholesale increased 55% YoY.
Vireo Growth (OTCQX: VREOF) will release fourth quarter and full year 2025 financial results on Tuesday, March 17, 2026, before market open. Management will host a conference call the same day at 8:00 a.m. ET (7:00 a.m. CT) to discuss results and answer investor questions.
Dial-in details: 1-800-715-9871 (US/Canada) or 1-646-307-1963 (International), conference ID 9471311. A live audio webcast will be available in the company’s Investor Relations Events & Presentations section at the provided Q4 events link.
Vireo Growth (OTCQX: VREOF) entered a nonbinding MOU to acquire The Hawthorne Gardening Company from ScottsMiracle-Gro in a planned share-based transaction expected to close in the first fiscal quarter of 2026. Vireo intends to appoint Chris Hagedorn to its board upon completion, and Scotts will transition to an equity participation arrangement.
The proposed deal brings Hawthorne's indoor and hydroponic gardening platform into Vireo's operations and deepens collaboration with Scotts while subject to customary closing conditions and final documentation.
Vireo Growth (OTCQX: VREOF) agreed to acquire Eaze Inc., adding operations in California, Florida and expanding in Colorado. The deal expands Vireo’s footprint to 10 states with 166 dispensaries and about 800,000 sq. ft. of cultivation and production.
Eaze operates 65 active retail locations, has completed over 12 million deliveries, and brings delivery coverage across major California metros and 39 Florida stores with ~64,000 sq. ft. canopy. Consideration is ~$47.0M paid as ~84 million subordinate voting shares at a deemed price of US$0.56, with an earn-out potential tied to 3.84x adjusted EBITDA payable in shares (floor price $1.05 or VWAP). Closing is expected in H1 2026 and remains subject to customary approvals and closing adjustments.
Vireo Growth (CSE: VREO; OTCQX: VREOF) announced it will acquire additional outstanding senior secured convertible notes of Medicine Man Technologies (dba Schwazze).
The notes have approximately $2.6 million principal plus accrued interest and will be purchased at a substantial discount for approximately $1.6 million payable in subordinate voting shares at $0.54 per share. Upon closing, expected later this month, Vireo will hold about 89% of outstanding senior secured convertible notes of Schwazze. Completion is subject to customary conditions and approvals. The share consideration will be subject to Canadian resale restrictions and CSE hold periods.
Vireo Growth (OTCQX: VREOF) entered a definitive Asset Purchase Agreement to acquire certain retail assets and properties of PharmaCann in Colorado for approximately $49.0 million payable in subordinate voting shares, plus assumption of certain liabilities. The acquisition adds 17 dispensaries and expands Vireo’s Colorado footprint to 41 active dispensaries. Share consideration is subject to adjustments for inventory and trade payables and will carry customary Canadian resale and CSE hold restrictions. Parties also signed a Management Services Agreement for Vireo to operate the acquired dispensaries through closing, which is expected in 1H 2026, subject to regulatory approvals and closing conditions.
Vireo Growth (OTCQX: VREOF) reported Q3 2025 GAAP revenue of $91.7M, up 264% year‑over‑year, driven by recent M&A and organic portfolio growth. GAAP gross profit was $37.4M (40.8% margin) and adjusted gross profit was $50.8M (55.4% margin). The company completed refinancing of senior secured debt, which is expected to reduce annualized interest expense by $10M. Cash on hand at September 30, 2025 was $117.5M and total current assets (excl. NY assets held for sale) were $191.1M. Vireo closed transactions to acquire Schwazze secured convertible notes and entered a restructuring plan that contemplates a UCC sale transferring a majority of Schwazze assets to a Vireo‑majority entity. Vireo also reached a settlement with Verano valued at approximately $10M.
Vireo Growth (OTCQX: VREOF) will release third fiscal quarter results for the period ended September 30, 2025 on Wednesday, November 12, 2025 before market open.
Management will host a conference call the same day at 8:30 a.m. ET (7:30 a.m. CT). Dial-in numbers: 1-800-715-9871 (US/Canada toll-free) or 1-646-307-1963 (international toll). Conference ID: 7974705. A live audio webcast will be available in the Events & Presentations section of the company investor relations site and at https://events.q4inc.com/attendee/235390523.